Fatigue - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Fatigue - Pipeline Review, H2 2016

Fatigue - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Fatigue - Pipeline Review, H2 2016
Published Jul 13, 2016
55 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Fatigue - Pipeline Review, H2 2016, provides an overview of the Fatigue pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fatigue
- The report reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fatigue therapeutics and enlists all their major and minor projects
- The report assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fatigue

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fatigue
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective

  
Source:
Document ID
GMDHC8223IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Fatigue Overview61
Therapeutics Development71
  Pipeline Products for Fatigue Overview71
Fatigue Therapeutics under Development by Companies81
Fatigue Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Fatigue Products under Development by Companies121
Fatigue Companies Involved in Therapeutics Development135
  BioLite, Inc.131
  Biovista Inc.141
  Grifols, S.A.151
  Hemispherx Biopharma, Inc.161
  MultiCell Technologies, Inc.171
Fatigue Therapeutics Assessment1810
  Assessment by Monotherapy Products181
  Assessment by Combination Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2815
  (lofepramine hydrochloride + phenylalanine) Drug Profile281
  alpha-1 proteinase inhibitor (human) Drug Profile291
  BLI-1402 Drug Profile301
  Recombinant A1PI Drug Profile312
  rintatolimod Drug Profile339
  Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis Drug Profile421
Fatigue Dormant Projects431
Fatigue Product Development Milestones4410
  Featured News &Press Releases441
    Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Expert Review of Clinical Pharmacology441
    Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke451
    Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen451
    Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study461
    Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms471
    Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe471
    Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations481
    May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations491
    May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets491
    Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference501
    Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference511
    Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries511
    Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen511
    Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen521
    Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012531
Appendix542
  Methodology541
  Coverage541
  Secondary Research541
  Primary Research541
  Expert Panel Validation541
  Contact Us541
  Disclaimer551

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Fatigue - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fatigue-Pipeline-Review-H2-2016-2088-16158>
  
APA:
Global Markets Direct - Market Research. (2016). Fatigue - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fatigue-Pipeline-Review-H2-2016-2088-16158>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.